Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. This evidence concerns the gene MCL1 and thyroid gland papillary carcinoma.